Clinical Study

Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study

Table 1

Patient characteristics and DEXA parameters at baseline.

CharacteristicsOverall population ()

Age at study entry (years) (49.5-80.4)
Age at menopause (years) (35.0-55.0)
Smoking status
 Never51 (85)
 Former8 (13.3)
 Current1 (1.7)
BMI (kg/m2) (18.8-31.9)
SBP (mmHg) (100-172)
DBP (mmHg) (55-88)
HR (50-89)
Comorbidities
 Dyslipidemia52 (86.7)
 Hypercolesterolemia48 (80)
 Hypertension42 (70)
 Hypothyroidism30 (50)
 Hypo-vitB12 or folate6 (10)
 DM22 (3.3)
DEXA parameter
-score L1-L4 (−4.2-0.8)
-score FN (−3.3-0.6)
-score TF (−3.4-0.7)
BMD (g/cm2) L1-L4 (0.542-0.935)
BMD (g/cm2) FN (0.485-0.739)
BMD (g/cm2) TF (0.530-0.923)

Data are expressed as deviation (SD) and range (min-max), or frequencies ( [%]). Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; vitB12: vitamin B12; DM2: diabetes mellitus type 2; L1-L4: lumbar spine; FN: femoral neck; TF: total femur; BMD: bone mineral density.